$LLY · Eli Lilly and Company

On October 19, 2026, Ralph Alvarez, a director of Eli Lilly and Company, reported an acquisition of common stock in a Form 4 filing with the SEC. The filing states that he acquired 10.0107 shares at a price of $1,240.34 per share. According to the explanation, Mr. Alvarez elected to defer cash compensation as stock units under the Lilly Directors’ Deferral Plan, and the shares acquired pursuant to this filing will be settled in common stock following his separation from service.

Following the reported transaction, Mr. Alvarez directly beneficially owned 55,848.2299 shares of Lilly common stock. The filing also lists 758 shares held indirectly by a trust, with the reporting person disclaiming beneficial ownership except to the extent of his pecuniary interest.